Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00943592 | Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 82 | University of ChicagoOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT00028899 | Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 47 | Children's Oncology GroupNETWORK | 3 | Feb 20, 2014 | clinicaltrials |
| NCT00125840 | Clofarabine in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT01455506 | PRO#0118: Decitabine Plus Mini Flu-Bu | completed | Phase 1 | 20 | Hackensack Meridian HealthOTHER | 1 | Feb 4, 2014 | clinicaltrials |
| NCT01068301 | A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | completed | Phase 1 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Jan 1, 2014 | clinicaltrials |
| NCT00005845 | Tipifarnib in Treating Patients With Myelodysplastic Syndromes | completed | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00911066 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia | completed | Phase 1 | 72 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT00098423 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301938 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00304018 | Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 5 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00049686 | VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00064090 | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00070538 | VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | completed | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00003619 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | — | Drexel University College of MedicineOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00002890 | Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00006040 | Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00006098 | PS-341 in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00042900 | Pyroxamide in Treating Patients With Advanced Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00022048 | Bevacizumab in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | — | Stanford UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00357305 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00038051 | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00278330 | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00003406 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer | completed | Phase 1 / Phase 2 | 30 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00823524 | Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00002980 | Decitabine in Treating Patients With Melanoma or Other Advanced Cancer | completed | Phase 1 | — | California Cancer ConsortiumNETWORK | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00005967 | Tipifarnib in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00114257 | Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00003997 | 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00095797 | XK469R in Treating Patients With Refractory Hematologic Cancer | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00230321 | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 21 | Peter L GreenbergOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00003451 | Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00003415 | Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 26 | University of ArizonaOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00005064 | PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005942 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006213 | BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00087204 | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00004245 | Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00003959 | Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00098826 | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00012376 | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00004918 | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00357708 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00295971 | Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | completed | Phase 1 | 21 | University of California, San FranciscoOTHER | 1 | Nov 12, 2012 | clinicaltrials |
| NCT00038831 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2014source: clinicaltrials